On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…
![Sci Writers / shutterstock.com](https://www.the-rheumatologist.org/wp-content/uploads/2021/08/THR_0821_pg1a-slider-150x150.png)